A breakthrough, radiation-free 3D breast imaging platform racing to scale—where 2026 growth hinges on distribution execution and cracking the reimbursement code.
Overview
QT Imaging Holdings (QTI) is commercializing an automated breast imaging platform built on transmission and reflection ultrasound tomography, with its flagship QT Breast Acoustic CT (BACT) scanner positioned as a radiation-free, non-invasive 3D imaging alternative intended to improve detection and characterization—especially for women with dense breast tissue, a large underserved population where mammography can miss lesions. The company is transitioning from a primarily hardware-revenue model to a hybrid hardware + SaaS model anchored by the QTI Cloud Platform, which aims to deliver recurring revenue through cloud-based reconstruction, advanced visualization, AI-ready analytics, and tissue biomarker tools (including collaboration elements with Olea Medical). Financially, the company is in rapid commercialization mode: 2024 revenue rose to ~$4.88M (from ~$0.04M in 2023), and 2025 revenue exceeded $18M via 40 scanner shipments, with customers split between U.S. distribution (Canon/NXC with MOQ structure) and international distributors (Saudi Arabia and UAE). FDA Breakthrough Device Designation and FDA clearance as supplemental screening strengthen the clinical positioning, but the investment hinges on scaling shipments, expanding the installed base, and—most critically—achieving standardized reimbursement via dedicated CPT pathways. The Nasdaq uplisting (Jan 2026) and an $18.2M PIPE financing improved visibility and liquidity, yet the company remains loss-making with internal-control remediation and dilution risk still central to the story.